Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
AssigneeVerimmune Inc.
InventorsJoshua Weiyuan Wang, Nattha Ingavat
Life of this patent
Estimating the term…
Abstract
This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.
Claims36
A virus-like particle (VLP), comprising:
- papilloma virus L1 protein, and
- at least one antigen comprising at least one T cell epitope,
- wherein the at least one antigen is attached to the VLP,
- wherein the T cell epitope is from a human pathogen heterologous to the papilloma virus of the VLP,
- wherein the at least one antigen is conjugated to a cysteine, lysine, or arginine residue of the L1 protein, and
- wherein release of the antigen from the VLP in a tumor microenvironment results in complexation of the antigen with a major histocompatibility (MHC) molecule present on a tumor cell surface resulting in activation of T cells, thereby inhibiting growth of the tumor cell.
A method of inhibiting tumor growth, tumor progression, or tumor metastasis in a subject in need thereof, which comprises contacting a tumor cell or cancer cell with an effective amount of a virus-like particle (VLP) composition, wherein the VLP comprises:
- a papilloma virus L1 protein, and
- at least one antigen comprising at least one T cell epitope,
- wherein the at least one antigen is attached to the VLP,
- wherein the T cell epitope is from a human pathogen heterologous to the papilloma virus of the VLP,
- wherein the at least antigen is conjugated to a cysteine, lysine, or arginine residue of the L1 protein, and
- wherein release of the antigen from the VLP in a tumor microenvironment results in complexation of the antigen with a major histocompatibility (MHC) molecule present on a tumor cell surface, activating T cells, and thereby resulting in inhibition of growth of the tumor cell.
A virus-like particle (VLP), comprising:
- papilloma virus L1 protein, and
- at least one antigen comprising at least one T cell epitope,
- wherein the at least one antigen is attached to the VLP,
- wherein the T cell epitope is from a human pathogen heterologous to the papilloma virus of the VLP,
- wherein the at least antigen is conjugated to a cysteine, lysine, or arginine residue of the L1 protein, and
- wherein about 35 to 100 percentage of the cysteine, lysine, or arginine residue of the L1 protein are conjugated to an antigen.
Dependencies are inferred from the claim text.